 Cytokinetics Inc NASDAQ: CYTK revealed in an SEC filing that Astellas Pharma Inc OTCMKTS: ALPMY is walking away from a pact to research and develop skeletal sarcomere activators for diseases associated with muscle weakness. Astellas had extended the research pact initially set to expire on December 31 last year, through March of this year. 